Skip to main content

Table 1 Demographic, clinical and immunological characteristics of the patients a

From: Circulating levels of soluble MER in lupus reflect M2c activation of monocytes/macrophages, autoantibody specificities and disease activity

Characteristics

Total patients

(N = 107)

Matched patients

(N = 45)

Matched controls

(N = 45)

Age (years)

39.6 ± 14.1

46.7 ± 15.4

45.4 ± 15.9

Sex (F:M ratio)

3.9:1

3.1:1

3.1:1

Ethnicity

   

Caucasian (%)

88.9

86.9

86.9

African (%)

6.7

6.5

6.5

Asian (%)

2.2

3.7

3.7

American Indian (%)

2.2

2.8

2.8

ACR total (number of criteria met)

5.51 ± 1.69

5.52 ± 1.69

 

Antichromatin Ab

32.7

28.9

 

Anti-dsDNA Ab (Crithidia luciliae test) (%)

27.1

33.3

 

Anticardiolipin IgG Ab (%)

38.3

28.9

 

LAC (%)

13.1

11.1

 

Anti-Smith Ab (%)

18.7

11.1

 

Anti-RNP Ab (%)

20.6

17.8

 

Anti-Ro/SSA (Ro52/60 kDa) Ab (%)

38.3 (21.5/34.6)

31.1 (17.8/28.9)

 

Anti-La/SSB (anti-Ro60 + anti-La) Ab (%)

16.8 (15.0)

15.6 (13.3)

 

CH50 <40 (U/ml)

51.4

55.6

 

C4 <16 (mg/dl)

35.5

44.4

 

SLEDAI score

5.29 ± 4.20

5.02 ± 3.26

 

Renal involvement (%)

13.1

24.4

 

(BILAG grades A to C)

Mucocutaneous involvement (%)

68.2

57.8

 

Musculoskeletal involvement (%)

77.6

66.7

 

Cardiovascular/respiratory involvement (%)

14

15.6

 

Hematological involvement (%)

37.4

31.1

 

Vasculitis (%)

53.3

53.3

 

Neurological involvement (%)

3.7

4.4

 

BILAG total score

6.17 ± 4.53

5.70 ± 3.93

 

Gas6 plasma levels (ng/ml)

18.81 ± 8.67

17.64 ± 7.10

15.89 ± 6.88

Free protein S plasma levels (μg/ml)

6.78 ± 2.36

6.37 ± 1.79

6.91 ± 1.74

  1. aAb, antibody; ACR total, number of American Rheumatism Association 1982 revised criteria for classification of systemic lupus erythematosus; BILAG, British Isles Lupus Assessment Group index; C4, complement fraction 4; CH50, 50% hemolytic complement activity of serum; dsDNA, double-stranded DNA; Gas6, growth arrest–specific 6; IgG, immunoglobulin G; LAC, lupus anticoagulant; RNP, ribonucleoprotein; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SSA, Sjögren’s syndrome antigen A; SSB, Sjögren’s syndrome antigen B.